BibTex RIS Kaynak Göster

Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi

Yıl 2019, Cilt: 29 Sayı: 4, 194 - 200, 01.12.2019

Öz

Amaç: Çalışmamızda boy kısalığı olan çocuklardaki Ürotensin 2’nin serum düzeylerini araştırarak İGF-1 ve İGFBP-3 gibi büyümeden sorumlu olan endojen maddeler arasındaki korelasyonu değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamızda 150 hasta ve 30 sağlıklı çocuk değerlendirmeye alındı. Bunlar kontrol, ailevi boy kısalığı, yapısal boy kısalığı, malnütrisyon ve çölyak olacak şekilde 5 gruba ayrıldı. Bunlarda kendi içinde İGF-1 ve İGFBP-3 düzeyleri düşük yada normal olacak şekilde gruplandırıldı. Bulgular: İGF-1 düzeyi normal olan ailevi boy kısalığı olan çocukların, düşük İGF-1 düzeyi olan yapısal boy kısalığı, malnütrisyonlu ve çölyak grubundaki çocukların serum Ürotensin 2 düzeyleri kontrol grubuna göre yüksek bulunmuştur. İGFBP-3 düzeylerine göre ise tüm gruplarda Ürotensin 2 düzeyi kontrole göre yüksek bulunmuştur. Sonuç: Çalışmamızda Ürotensin 2’nin çocuklarda büyüme gelişme geriliği ve boy kısalığı fizyopatolojisinderol alabileceği düşünülmektedir

Kaynakça

  • Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018;14:285-300.
  • Wang B, Qin C, Zhang C, et al. Differential involvement of signaling pathways in the regulation of growth hormone re- lease by somatostatin and growth hormone-releasing hor- mone in orange-spotted grouper (Epinephelus coioides). Mol Cell Endocrinol 2014;382:851-9.
  • Chinoy A, Murray PG. Diagnosis of growth hormone defi- ciency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:737-47.
  • Wong SC, Dobie R, Altowati MA, et al. Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Endocr Rev 2016;37:62-110.
  • Murray PG, Clayton PE, Chernausek SD. A genetic appro- ach to evaluation of short stature of undetermined cause. Lancet Diabetes Endocrinol 2018;6:564-74.
  • Boucher J, Softic S, El Ouaamari A, et al. Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Develop- ment and Function. Diabetes 2016;65:2201-13.
  • Soni H, Adebiyi A. Urotensin II-induced store-operated Ca(2+) entry contributes to glomerular mesangial cell pro- liferation and extracellular matrix protein production un- der high glucose conditions. Sci Rep 2017;7:18049.
  • Matsumoto T, Watanabe S, Kobayashi S, et al. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. Rejuvenation Res 2017;20:134-45.
  • Cadirci E, Halici Z, Yayla M, et al. Blocking of urotensin re- ceptors as new target for treatment of carrageenan induced inflammation in rats. Peptides 2016;82:35-43.
  • Satiroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158-63.
  • Malagon MM, Molina M, Gahete MD, et al. Urotensin II and urotensin II-related peptide activate somatostatin re- ceptor subtypes 2 and 5. Peptides 2008;29:711-20.
  • Rivas RJ, Nishioka RS, Bern HA. In vitro effects of soma- tostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. Gen Comp Endocrinol 1986;63:245-51.
  • Sun C, Duan D, Li B, et al. UII and UT in grouper: clo- ning and effects on the transcription of hormones related to growth control. J Endocrinol 2014;220:35-48.
  • Argente J, Luis AP-J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab 2018;32:499- 522.
  • Gönç EN, Özön ZA, Alikaşifoğlu A, Kandemir N. Çocuk- larda büyümenin değerlendirilmesi ve boy kısalığında tanı- sal yaklaşım Çoc Sağ ve Hast Derg 2015;58:85.
  • Ashpole NM, Sanders JE, Hodges EL, Yan H, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol 2015;68:76-81.
  • Ross B, McKendy K, Giaid A. Role of urotensin II in he- alth and disease. Am J Physiol Regul Integr Comp Physiol 2010;298:1156-72.
  • Palabiyik SS, Karakus E, Akpinar E, et al. The Role of Uro- tensin Receptors in the Paracetamol-Induced Hepatotoxi- city Model in Mice: Ameliorative Potential of Urotensin II Antagonist. Basic Clin Pharmacol Toxicol 2016;118:150-69.
  • Tostivint H, Ocampo D, Bergqvist CA, et al. Molecular evolution of GPCRs: Somatostatin/urotensin II receptors. J Mol Endocrinol 2014;52:61-86.
  • Liu Y, Lu D, Zhang Y, et al. The evolution of somatostatin in vertebrates. Gene 2010;463:21-8.
  • Tostivint H, Quan FB, Bougerol M, Kenigfest NB, Lihr- mann I. Impact of gene/genome duplications on the evo- lution of the urotensin II and somatostatin families. Gen Comp Endocrinol 2013;188:110-7.
  • Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, et al. Urotensin II modulates rapid eye movement sleep throu- gh activation of brainstem cholinergic neurons. J Neurosci 2005;25:5465-74.
  • Kim TW, Jeong JH, Hong SC. The impact of sleep and cir- cadian disturbance on hormones and metabolism. Int J En- docrinol 2015;15:5917-29.
  • Vaudry H, Leprince J, Chatenet D, et al. International Uni- on of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from struc- ture to function. Pharmacol Rev 2015;67:214-58.
  • Bucharles C, Bizet P, Arthaud S, et al. Concordant localiza- tion of functional urotensin II and urotensin II-related pep- tide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. J Comp Neurol 2014;522:2634-49.
  • Quan FB, Dubessy C, Galant S, et al. Comparative distribu- tion and in vitro activities of the urotensin II-related pepti- des URP1 and URP2 in zebrafish: evidence for their colo- calization in spinal cerebrospinal fluid-contacting neurons. PLoS One 2015;10:1192-90.
  • Yasuda T, Masaki T, Gotoh K, et al. Intracerebroventricular administration of urotensin II regulates food intake and sy- mpathetic nerve activity in brown adipose tissue. Peptides 2012;35:131-5.
  • Cederholm T, Barazzoni R, Austin P, et al. ESPEN guide- lines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49-64.
  • Guerra RS, Fonseca I, Sousa AS, et al. ESPEN diagnostic criteria for malnutrition - A validation study in hospitalized patients. Clin Nutr 2017;36:1326-32.
  • Güleç SG UN, Polat S, Yağar G, Hatipoğlu N,. Hastane- de yatan üç yaş altı çocuklarda malnütrisyon durumu- nun değerlendirilmesi. Şişli Etfal Hastanesi Tıp Bülteni 2011;45:124-29.
  • Serin Y, Akbulut G. Celiac Disease and the Contemporary Approach to Gluten-Free Diet Treatment. Turkiye Klinikle- ri J Health Sci 2017;2:192-200.
  • Soylu ÖB, Ecevit ÖÇ. Çölyak hastalığı tanısı ile izlenen ol- guların klinik değerlendirmesi. İzmir Dr Behçet Uz Çocuk Hast Dergisi 2013;3:38-43.
  • Kuloglu Z. Celiac Disease. Turkish J Pediatr Dis 2014;2:105- 11.
  • Demirçeken FG. Gluten enteropatisi (çölyak hastalığı): Klasik bir öykü ve güncel gelişmeler. Günc gastroenterol 2011;15:58-72.
  • Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical gui- delines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.
Yıl 2019, Cilt: 29 Sayı: 4, 194 - 200, 01.12.2019

Öz

Objective: In this study, we aimed to evaluate the correlation between endogenous substances responsible for growth such as IGF-1 and IGFBP-3 by investigating serum levels of Urotensin 2 in children with short stature. Material and Methods: In this study, 150 patients short stature and 30 healthy children were evaluated. These were divided into 5 groups, including control, family short stature, structural short stature, malnutrition and celiac disease.The IGF-1 and IGFBP-3 levels were determined as low or normal in these groups.Results: Serum Urotensin 2 levels were found to be higher in structural short stature, malnutrition and celiac disease with low IGF-1 levels and familial short stature with normal IGF-1 levels than control. According to IGFBP-3 levels, Urotensin2 levels were higher in all groups compared to control. Conclusion: In our study, Urotensin 2 may play a role in the pathophysiology of growth retardation and shortening in children

Kaynakça

  • Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018;14:285-300.
  • Wang B, Qin C, Zhang C, et al. Differential involvement of signaling pathways in the regulation of growth hormone re- lease by somatostatin and growth hormone-releasing hor- mone in orange-spotted grouper (Epinephelus coioides). Mol Cell Endocrinol 2014;382:851-9.
  • Chinoy A, Murray PG. Diagnosis of growth hormone defi- ciency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:737-47.
  • Wong SC, Dobie R, Altowati MA, et al. Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Endocr Rev 2016;37:62-110.
  • Murray PG, Clayton PE, Chernausek SD. A genetic appro- ach to evaluation of short stature of undetermined cause. Lancet Diabetes Endocrinol 2018;6:564-74.
  • Boucher J, Softic S, El Ouaamari A, et al. Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Develop- ment and Function. Diabetes 2016;65:2201-13.
  • Soni H, Adebiyi A. Urotensin II-induced store-operated Ca(2+) entry contributes to glomerular mesangial cell pro- liferation and extracellular matrix protein production un- der high glucose conditions. Sci Rep 2017;7:18049.
  • Matsumoto T, Watanabe S, Kobayashi S, et al. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. Rejuvenation Res 2017;20:134-45.
  • Cadirci E, Halici Z, Yayla M, et al. Blocking of urotensin re- ceptors as new target for treatment of carrageenan induced inflammation in rats. Peptides 2016;82:35-43.
  • Satiroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158-63.
  • Malagon MM, Molina M, Gahete MD, et al. Urotensin II and urotensin II-related peptide activate somatostatin re- ceptor subtypes 2 and 5. Peptides 2008;29:711-20.
  • Rivas RJ, Nishioka RS, Bern HA. In vitro effects of soma- tostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. Gen Comp Endocrinol 1986;63:245-51.
  • Sun C, Duan D, Li B, et al. UII and UT in grouper: clo- ning and effects on the transcription of hormones related to growth control. J Endocrinol 2014;220:35-48.
  • Argente J, Luis AP-J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab 2018;32:499- 522.
  • Gönç EN, Özön ZA, Alikaşifoğlu A, Kandemir N. Çocuk- larda büyümenin değerlendirilmesi ve boy kısalığında tanı- sal yaklaşım Çoc Sağ ve Hast Derg 2015;58:85.
  • Ashpole NM, Sanders JE, Hodges EL, Yan H, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol 2015;68:76-81.
  • Ross B, McKendy K, Giaid A. Role of urotensin II in he- alth and disease. Am J Physiol Regul Integr Comp Physiol 2010;298:1156-72.
  • Palabiyik SS, Karakus E, Akpinar E, et al. The Role of Uro- tensin Receptors in the Paracetamol-Induced Hepatotoxi- city Model in Mice: Ameliorative Potential of Urotensin II Antagonist. Basic Clin Pharmacol Toxicol 2016;118:150-69.
  • Tostivint H, Ocampo D, Bergqvist CA, et al. Molecular evolution of GPCRs: Somatostatin/urotensin II receptors. J Mol Endocrinol 2014;52:61-86.
  • Liu Y, Lu D, Zhang Y, et al. The evolution of somatostatin in vertebrates. Gene 2010;463:21-8.
  • Tostivint H, Quan FB, Bougerol M, Kenigfest NB, Lihr- mann I. Impact of gene/genome duplications on the evo- lution of the urotensin II and somatostatin families. Gen Comp Endocrinol 2013;188:110-7.
  • Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, et al. Urotensin II modulates rapid eye movement sleep throu- gh activation of brainstem cholinergic neurons. J Neurosci 2005;25:5465-74.
  • Kim TW, Jeong JH, Hong SC. The impact of sleep and cir- cadian disturbance on hormones and metabolism. Int J En- docrinol 2015;15:5917-29.
  • Vaudry H, Leprince J, Chatenet D, et al. International Uni- on of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from struc- ture to function. Pharmacol Rev 2015;67:214-58.
  • Bucharles C, Bizet P, Arthaud S, et al. Concordant localiza- tion of functional urotensin II and urotensin II-related pep- tide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. J Comp Neurol 2014;522:2634-49.
  • Quan FB, Dubessy C, Galant S, et al. Comparative distribu- tion and in vitro activities of the urotensin II-related pepti- des URP1 and URP2 in zebrafish: evidence for their colo- calization in spinal cerebrospinal fluid-contacting neurons. PLoS One 2015;10:1192-90.
  • Yasuda T, Masaki T, Gotoh K, et al. Intracerebroventricular administration of urotensin II regulates food intake and sy- mpathetic nerve activity in brown adipose tissue. Peptides 2012;35:131-5.
  • Cederholm T, Barazzoni R, Austin P, et al. ESPEN guide- lines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49-64.
  • Guerra RS, Fonseca I, Sousa AS, et al. ESPEN diagnostic criteria for malnutrition - A validation study in hospitalized patients. Clin Nutr 2017;36:1326-32.
  • Güleç SG UN, Polat S, Yağar G, Hatipoğlu N,. Hastane- de yatan üç yaş altı çocuklarda malnütrisyon durumu- nun değerlendirilmesi. Şişli Etfal Hastanesi Tıp Bülteni 2011;45:124-29.
  • Serin Y, Akbulut G. Celiac Disease and the Contemporary Approach to Gluten-Free Diet Treatment. Turkiye Klinikle- ri J Health Sci 2017;2:192-200.
  • Soylu ÖB, Ecevit ÖÇ. Çölyak hastalığı tanısı ile izlenen ol- guların klinik değerlendirmesi. İzmir Dr Behçet Uz Çocuk Hast Dergisi 2013;3:38-43.
  • Kuloglu Z. Celiac Disease. Turkish J Pediatr Dis 2014;2:105- 11.
  • Demirçeken FG. Gluten enteropatisi (çölyak hastalığı): Klasik bir öykü ve güncel gelişmeler. Günc gastroenterol 2011;15:58-72.
  • Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical gui- delines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.
Toplam 35 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Original Article
Yazarlar

Muhammed Yayla Bu kişi benim

Damla Binnetoğlu Bu kişi benim

Sefer Üstebay Bu kişi benim

Hayrunisa Bekis Bozkurt Bu kişi benim

Ömer Ertekin Bu kişi benim

Döndü Ülker Üstebay Bu kişi benim

Yayımlanma Tarihi 1 Aralık 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 29 Sayı: 4

Kaynak Göster

Vancouver Yayla M, Binnetoğlu D, Üstebay S, Bozkurt HB, Ertekin Ö, Üstebay DÜ. Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi. Genel Tıp Derg. 2019;29(4):194-200.